These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
322 related articles for article (PubMed ID: 32683296)
41. Epitopes for a 2019-nCoV vaccine. Lucchese G Cell Mol Immunol; 2020 May; 17(5):539-540. PubMed ID: 32094505 [No Abstract] [Full Text] [Related]
42. Lee CH; Koohy H F1000Res; 2020; 9():145. PubMed ID: 32269766 [No Abstract] [Full Text] [Related]
43. Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2. Konwarh R Front Immunol; 2020; 11():1531. PubMed ID: 32655584 [No Abstract] [Full Text] [Related]
45. Epitope-based peptide vaccine design and target site depiction against Middle East Respiratory Syndrome Coronavirus: an immune-informatics study. Tahir Ul Qamar M; Saleem S; Ashfaq UA; Bari A; Anwar F; Alqahtani S J Transl Med; 2019 Nov; 17(1):362. PubMed ID: 31703698 [TBL] [Abstract][Full Text] [Related]
46. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. Kanduc D; Shoenfeld Y Immunol Res; 2020 Oct; 68(5):310-313. PubMed ID: 32946016 [No Abstract] [Full Text] [Related]
47. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines. Salvatori G; Luberto L; Maffei M; Aurisicchio L; Roscilli G; Palombo F; Marra E J Transl Med; 2020 Jun; 18(1):222. PubMed ID: 32493510 [TBL] [Abstract][Full Text] [Related]
48. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. van Doremalen N; Lambe T; Spencer A; Belij-Rammerstorfer S; Purushotham JN; Port JR; Avanzato VA; Bushmaker T; Flaxman A; Ulaszewska M; Feldmann F; Allen ER; Sharpe H; Schulz J; Holbrook M; Okumura A; Meade-White K; Pérez-Pérez L; Edwards NJ; Wright D; Bissett C; Gilbride C; Williamson BN; Rosenke R; Long D; Ishwarbhai A; Kailath R; Rose L; Morris S; Powers C; Lovaglio J; Hanley PW; Scott D; Saturday G; de Wit E; Gilbert SC; Munster VJ Nature; 2020 Oct; 586(7830):578-582. PubMed ID: 32731258 [TBL] [Abstract][Full Text] [Related]
49. An Effective COVID-19 Vaccine Needs to Engage T Cells. Sauer K; Harris T Front Immunol; 2020; 11():581807. PubMed ID: 33117391 [No Abstract] [Full Text] [Related]
50. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. Grifoni A; Sidney J; Zhang Y; Scheuermann RH; Peters B; Sette A Cell Host Microbe; 2020 Apr; 27(4):671-680.e2. PubMed ID: 32183941 [TBL] [Abstract][Full Text] [Related]
51. In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction. Silva-Arrieta S; Goulder PJR; Brander C PLoS Pathog; 2020 Jun; 16(6):e1008607. PubMed ID: 32497149 [No Abstract] [Full Text] [Related]
52. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies. Papageorgiou AC; Mohsin I Cells; 2020 Oct; 9(11):. PubMed ID: 33105869 [TBL] [Abstract][Full Text] [Related]
53. SARS-CoV-2: A New Song Recalls an Old Melody. Subbarao K Cell Host Microbe; 2020 May; 27(5):692-694. PubMed ID: 32407706 [TBL] [Abstract][Full Text] [Related]
54. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Vojdani A; Kharrazian D Clin Immunol; 2020 Aug; 217():108480. PubMed ID: 32461193 [No Abstract] [Full Text] [Related]
55. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645 [TBL] [Abstract][Full Text] [Related]
56. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192 [TBL] [Abstract][Full Text] [Related]
57. The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. Duan L; Zheng Q; Zhang H; Niu Y; Lou Y; Wang H Front Immunol; 2020; 11():576622. PubMed ID: 33117378 [TBL] [Abstract][Full Text] [Related]
58. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development. Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK Front Immunol; 2020; 11():1880. PubMed ID: 32973779 [TBL] [Abstract][Full Text] [Related]
59. Designing a multi-epitope vaccine candidate to combat MERS-CoV by employing an immunoinformatics approach. Mahmud S; Rafi MO; Paul GK; Promi MM; Shimu MSS; Biswas S; Emran TB; Dhama K; Alyami SA; Moni MA; Saleh MA Sci Rep; 2021 Jul; 11(1):15431. PubMed ID: 34326355 [TBL] [Abstract][Full Text] [Related]
60. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance. Robson B Comput Biol Med; 2020 Jun; 121():103749. PubMed ID: 32568687 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]